Segulah II L.P has signed an agreement with listed pharmaceutical research company Medivir to acquire its subsidiary CCS.
Headquartered in Borlõnge north of Stockholm, CCS develops, manufactures and markets products for personal care and pharmaceuticals. Within pharmaceuticals, the company focuses on OTC and prescription based dermatology and ophthalmology products. Products are primarily sold through pharmacies but also through food retail chains in the Nordic countries and in the UK. During the past five years, the company has grown by more than 25% annually, while maintaining high and stable margins. Segulahs forecast for CCS in 2003 is revenue MSEK 170 with EBIT of MSEK 30 on 120 employees.
”CCS is a well managed company active in a niche with underlying growth and considerable development potential. We are pleased to have arranged a management buy-out of CCS from Medivir, a listed company for which CCS is not core business” says Christian Sievert, Managing Partner of Segulah.
”This shift in ownership takes place in a situation when CCS’ strong market position can be further leveraged with Segulah as an owner”, says Jonas Nilsson, CEO of CCS.
For further information, please contact:
Segulah: Christian Sievert, Managing Partner, +46 8 442 89 50 (office) or +46 708 66 96 94 (mobile)
CCS: Jonas Nilsson, CEO, +46 243 78100 (office) or +46 70 554 16 80 (mobile)